R&D Insights: How Jazz Pharmaceuticals plc and TG Therapeutics, Inc. Allocate Funds

Biopharma R&D: Jazz vs. TG Therapeutics' Spending Strategies

__timestampJazz Pharmaceuticals plcTG Therapeutics, Inc.
Wednesday, January 1, 20148518100031354781
Thursday, January 1, 201513525300043445817
Friday, January 1, 201616229700066489820
Sunday, January 1, 201719844200096886134
Monday, January 1, 2018226616000153793000
Tuesday, January 1, 2019299726000148369000
Wednesday, January 1, 2020335375000151934000
Friday, January 1, 2021505748000198532000
Saturday, January 1, 2022590453000112128000
Sunday, January 1, 202384965800076192000
Loading chart...

In pursuit of knowledge

R&D Spending: A Tale of Two Biopharma Giants

In the competitive world of biopharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Jazz Pharmaceuticals plc and TG Therapeutics, Inc. have shown distinct strategies in their R&D allocations over the past decade. From 2014 to 2023, Jazz Pharmaceuticals increased its R&D expenses by nearly 900%, peaking in 2023. This surge underscores their aggressive pursuit of new therapies and market expansion. In contrast, TG Therapeutics, Inc. exhibited a more modest growth in R&D spending, with a peak in 2021, reflecting a focused yet cautious approach. By 2023, Jazz Pharmaceuticals' R&D expenses were over 11 times higher than TG Therapeutics, highlighting their divergent paths in the biopharma landscape. This data not only reveals spending trends but also offers insights into each company's strategic priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025